Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

@article{Akuta2017LedipasvirPS,
  title={Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.},
  author={Norio Akuta and Hitomi Sezaki and Fumitaka Suzuki and Shunichiro Fujiyama and Yusuke Kawamura and Tetsuya Hosaka and Masahiro Kobayashi and Mariko Kobayashi and Satoshi Saitoh and Yoshiyuki Suzuki and Yasuji Arase and Kenji Ikeda and Hiromitsu Kumada},
  journal={Journal of medical virology},
  year={2017},
  volume={89 7},
  pages={
          1248-1254
        }
}
There is little information on retreatment efficacy and predictors of the combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir) for patients who fail to respond to NS5A inhibitors. NS5A resistance variants are known to persist for long periods after such treatment. Here, we evaluated 54 patients with chronic HCV genotype 1b infection, free of decompensated cirrhosis, and hepatocellular carcinoma, for sustained virological response after 12 weeks (SVR12) of once-daily treatment with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

  • Pawlotsky JM.
  • Gastroenterology 151:70-86.
  • 2016

Similar Papers

Loading similar papers…